View in EDS HTML Full Text PDF Full Text

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.

Saved in:
Bibliographic Details
Title: Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
Authors: Chmielecki J; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA., Gray JE; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Jhanelle.Gray@moffitt.org., Cheng Y; Jilin Provincial Cancer Hospital, Changchun, China., Ohe Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan., Imamura F; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan., Cho BC; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Lin MC; Division of Pulmonary and Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan., Majem M; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Shah R; Kent Oncology Centre, Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK., Rukazenkov Y; Oncology R&D, AstraZeneca, Cambridge, UK., Todd A; Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, UK., Markovets A; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA., Barrett JC; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA., Hartmaier RJ; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA., Ramalingam SS; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Source: Nature communications [Nat Commun] 2023 Jun 01; Vol. 14 (1), pp. 3179. Date of Electronic Publication: 2023 Jun 01.
Publication Type: Published Erratum
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37263992
AccessLevel: 2
PubTypeId: unknown
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Chmielecki+J%22">Chmielecki J</searchLink>; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Gray+JE%22">Gray JE</searchLink>; Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Jhanelle.Gray@moffitt.org.<br /><searchLink fieldCode="AU" term="%22Cheng+Y%22">Cheng Y</searchLink>; Jilin Provincial Cancer Hospital, Changchun, China.<br /><searchLink fieldCode="AU" term="%22Ohe+Y%22">Ohe Y</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Imamura+F%22">Imamura F</searchLink>; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Cho+BC%22">Cho BC</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lin+MC%22">Lin MC</searchLink>; Division of Pulmonary and Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan.<br /><searchLink fieldCode="AU" term="%22Majem+M%22">Majem M</searchLink>; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Shah+R%22">Shah R</searchLink>; Kent Oncology Centre, Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK.<br /><searchLink fieldCode="AU" term="%22Rukazenkov+Y%22">Rukazenkov Y</searchLink>; Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Todd+A%22">Todd A</searchLink>; Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Markovets+A%22">Markovets A</searchLink>; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Barrett+JC%22">Barrett JC</searchLink>; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Hartmaier+RJ%22">Hartmaier RJ</searchLink>; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ramalingam+SS%22">Ramalingam SS</searchLink>; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2023 Jun 01; Vol. 14 (1), pp. 3179. <i>Date of Electronic Publication: </i>2023 Jun 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Published Erratum
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE; PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37263992
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-023-38999-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3179
    Titles:
      – TitleFull: Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chmielecki J
      – PersonEntity:
          Name:
            NameFull: Gray JE
      – PersonEntity:
          Name:
            NameFull: Cheng Y
      – PersonEntity:
          Name:
            NameFull: Ohe Y
      – PersonEntity:
          Name:
            NameFull: Imamura F
      – PersonEntity:
          Name:
            NameFull: Cho BC
      – PersonEntity:
          Name:
            NameFull: Lin MC
      – PersonEntity:
          Name:
            NameFull: Majem M
      – PersonEntity:
          Name:
            NameFull: Shah R
      – PersonEntity:
          Name:
            NameFull: Rukazenkov Y
      – PersonEntity:
          Name:
            NameFull: Todd A
      – PersonEntity:
          Name:
            NameFull: Markovets A
      – PersonEntity:
          Name:
            NameFull: Barrett JC
      – PersonEntity:
          Name:
            NameFull: Hartmaier RJ
      – PersonEntity:
          Name:
            NameFull: Ramalingam SS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2023 Jun 01
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1